PositiveID Board Approves 1-for-25 Reverse Stock Split | GenomeWeb

NEW YORK (GenomeWeb News) – PositiveID said today its board has approved a 1-for-25 reverse stock split, commencing at the start of trading on April 23.

As a result of the reverse split, the number of PositiveID shares will be reduced to about 15 million shares. The company's ticker symbol will be PSIDD for about 20 trading days after the split to designate it is trading on a post-reverse split basis.

The company trades on the Over-The-Counter Bulletin Board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.